Potter van Loon B J, Kluft C, Radder J K, Blankenstein M A, Meinders A E
Department of Endocrinology, University Hospital, Leiden, The Netherlands.
Metabolism. 1993 Aug;42(8):945-9. doi: 10.1016/0026-0495(93)90005-9.
The cardiovascular risk factor plasminogen activator inhibitor type 1 (PAI-1) has been associated with abdominal obesity, hypertension, hypertriglyceridemia, hyperinsulinemia, glucose intolerance, and type II diabetes, conditions known to be linked with insulin resistance. To determine whether PAI-1 is related to insulin resistance, we studied nine obese nondiabetics and 10 obese type II diabetics by means of a sequential hyperinsulinemic euglycemic clamp study. Plasma PAI-1 antigen (Ag) correlated significantly with peripheral insulin resistance, represented by the insulin level at which peripheral glucose uptake (PGU) is half-maximal ([ED50PGU] r = .87, P < .001). Multiple regression analysis including indices of hepatic and peripheral insulin action, fasting plasma insulin levels, triglyceride levels, blood pressure (BP), waist to hip ratio (WHR), and body mass index (BMI) disclosed ED50PGU to account for 76% of the variance of PAI-1 Ag. We suggest that PAI-1 contributes to the increased cardiovascular risk encountered with insulin resistance.
心血管危险因素纤溶酶原激活物抑制剂1型（PAI-1）与腹型肥胖、高血压、高甘油三酯血症、高胰岛素血症、葡萄糖耐量异常及II型糖尿病相关，这些病症均已知与胰岛素抵抗有关。为确定PAI-1是否与胰岛素抵抗相关，我们通过连续高胰岛素正常血糖钳夹研究对9名肥胖非糖尿病患者和10名肥胖II型糖尿病患者进行了研究。血浆PAI-1抗原（Ag）与外周胰岛素抵抗显著相关，以外周葡萄糖摄取（PGU）达到最大值一半时的胰岛素水平表示（[ED50PGU]，r = 0.87，P < 0.001）。多元回归分析纳入了肝脏和外周胰岛素作用指标、空腹血浆胰岛素水平、甘油三酯水平、血压（BP）、腰臀比（WHR）及体重指数（BMI），结果显示ED50PGU可解释PAI-1 Ag变异的76%。我们认为PAI-1会增加胰岛素抵抗时所面临的心血管风险。
